

Stockholm, 31 January 2012

Wills Hughes-Wilson appointed Vice President Government Affairs & Policy

Wills Hughes-Wilson has been appointed Vice President, Government Affairs & Policy with responsibility for Sobi's contacts with all stakeholders in the health policy area.

Wills comes from Genzyme Corporation, now part of the French Sanofi Group, where she was Vice President Health/Market Access Policy, Europe. She joined Genzyme in 2005. Prior to Genzyme she was Executive Director of Emerging Biopharmaceutical Enterprises (EBE), a specialized group of the European Federation of Pharmaceuticals Industries & Associations (EFPIA) representing the interest of biotechnology companies in Europe. She has also worked in the animal health/veterinary medicines industry and at Ernst & Young Consulting.

Will Hughes Wilson, born in 1971, is an Honors graduate in Law from University of Durham in the UK. She will report to CEO Geoffrey McDonough and will be a member of the Executive Leadership Team, based in Brussels. She will assume her position in February 2012.

"We are very pleased to welcome Wills to Sobi. As one of the leading health policy experts in Europe within the orphan disease area, Wills is Chair of the joint EBE and EuropaBio Industry Task Force on Orphan Drugs and Rare Diseases, and is one of four industry members of the European Commission's newly established Committee of Experts on Rare Diseases (EUCERD). Wills will represent the patient focus and commitment to rare diseases of Sobi in the policy arena," says Geoffrey McDonough, CEO of Sobi.

For further information, please contact:

Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88

Swedish Orphan Biovitrum (Sobi)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 60 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ Stockholm. More information is available at www.sobi.com.

The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 31 January 2012 at 10.00 CET.